위내 풍선 시장 : 제품 유형, 충전재, 시술 방법, 유치 기간, 용도별 - 세계 시장 예측(2026-2032년)

The Intragastric Balloon Market is projected to grow by USD 41.75 million at a CAGR of 8.56% by 2032.

Intragastric balloons are minimally invasive obesity treatment devices placed in the stomach to create satiety, support portion control, and help patients achieve medically supervised weight loss without permanent anatomical alteration. Demand is anchored in a documented public health need: the World Health Organization reported that more than 2.5 billion adults were overweight in 2022, including over 890 million adults living with obesity.

The intragastric balloon market is positioned between lifestyle therapy and bariatric surgery, serving patients who need more than diet and exercise but may not qualify for, or may defer, surgical procedures. Commercial momentum depends on evidence-based patient selection, endoscopic capacity, reimbursement clarity, post-placement nutrition programs, and rigorous management of known device risks.

Transformative Shifts in the Intragastric Balloon Landscape

The intragastric balloon landscape is shifting from device-only weight loss toward integrated obesity care. Providers increasingly combine balloon placement with dietetics, behavioral coaching, metabolic monitoring, and digital follow-up to improve adherence after removal, since balloons are temporary therapies and durable outcomes require structured lifestyle support.

Competition is also being reshaped by pharmacotherapy, especially GLP-1 receptor agonists and dual incretin medicines, which have raised expectations for clinically meaningful weight loss. Rather than replacing intragastric balloons outright, these therapies are encouraging hybrid care pathways where balloons, medications, and bariatric procedures are matched to patient risk, affordability, contraindications, and treatment goals.

Cumulative Impact of Artificial Intelligence on Intragastric Balloons

Artificial intelligence is becoming a practical enabler across the intragastric balloon value chain. AI-supported screening can help clinicians evaluate BMI, comorbidities, prior procedures, medication use, nutritional risk, and contraindications, while analytics can flag patients who may need closer nutritional or behavioral support after placement.

AI also supports operational efficiency through automated scheduling, adverse-event surveillance, documentation review, coding support, and remote patient engagement. Its impact remains cumulative rather than standalone: AI does not replace clinical judgment or regulatory compliance, but it can improve consistency, patient retention, and real-world evidence generation when deployed under privacy, cybersecurity, and medical-device governance.

Key Regional Insights Across Major Intragastric Balloon Markets

North America remains a key adoption center because of established endoscopy infrastructure, FDA-cleared balloon systems, obesity-focused specialty care, and high disease prevalence; the CDC reported U.S. adult obesity at 40.3% for August 2021-August 2023. Europe benefits from specialist obesity centers, clinical guideline adoption, and EU medical-device oversight, while Asia-Pacific is expanding through private hospitals, rising metabolic disease burden, advanced endoscopy capabilities in major economies, and growing medical tourism in selected countries.

Latin America shows opportunity where self-pay obesity care and bariatric expertise are strong, especially in urban centers across Brazil and Mexico. The Middle East is supported by high diabetes and obesity awareness in Gulf markets and public health strategies that emphasize prevention and weight management, while Africa remains earlier-stage, with demand concentrated in private hospitals and constrained by affordability, trained specialists, endoscopy availability, and long-term follow-up capacity.

Key Group Insights for Intragastric Balloon Adoption

Across the European Union, harmonized medical-device rules and GDPR-driven data standards influence product access, post-market surveillance, clinical documentation, and digital follow-up models. G7 markets offer advanced clinical infrastructure, specialist obesity programs, and research capacity, while NATO countries overlap with many high-income health systems that prioritize safety reporting, procurement resilience, and continuity of medical-device supply.

ASEAN growth is tied to private care, urban obesity trends, rising noncommunicable disease awareness, and cross-border medical services in major hubs. GCC countries show strong potential due to obesity and diabetes prevention priorities, high specialist-care investment, and demand for minimally invasive weight-loss options. BRICS markets add scale through large patient populations and expanding healthcare access, but pricing, physician training, regulatory pathways, and reimbursement variability determine how quickly intragastric balloons move beyond premium self-pay segments.

Key Country Insights for Intragastric Balloon Growth

The United States leads in regulated commercial activity, supported by FDA device oversight, obesity medicine networks, and ambulatory endoscopy capacity, while Canada emphasizes specialist referral, provincial access dynamics, and safety oversight. Mexico and Brazil benefit from established bariatric communities, urban private healthcare capacity, and self-pay demand. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine endoscopy capacity with structured obesity services and clinical governance, while Russia presents access potential shaped by local regulation, purchasing power, and specialist availability.

China and India represent large long-term opportunities because of rising obesity, diabetes, and cardiometabolic risk burdens, though affordability, patient awareness, procedure access, and provider training remain decisive. Japan and South Korea bring advanced endoscopy capabilities, quality-focused adoption, and high procedural standards, while Australia supports medically supervised weight management through private hospitals, specialist clinic networks, and multidisciplinary obesity care pathways.

Actionable Recommendations for Intragastric Balloon Industry Leaders

Industry leaders should position intragastric balloons as part of a full obesity-care pathway rather than a stand-alone procedure. Differentiation should focus on documented weight-loss outcomes, adverse-event transparency, structured nutrition programs, patient education, and retention through the removal and maintenance phases.

Commercial teams should prioritize physician training, center-of-excellence partnerships, payer evidence, registry participation, and digital aftercare. Manufacturers and providers should also prepare for combination pathways with anti-obesity medications, ensuring protocols address sequencing, nutritional risk, contraindications, patient adherence, device removal planning, and long-term metabolic monitoring.

Research Methodology for Intragastric Balloon Analysis

This executive summary is based on secondary research from verified public sources, including the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration device communications, peer-reviewed obesity literature, clinical practice guidance, and publicly available regulatory information.

The analysis applies market triangulation across epidemiology, regulatory status, clinical workflow, provider infrastructure, regional access conditions, obesity-treatment pathways, and competitive dynamics across lifestyle therapy, pharmacotherapy, intragastric balloons, and bariatric surgery. Qualitative insights were normalized to avoid unsupported market sizing, market share, or forecasting and to maintain evidence-based interpretation for strategic decision-making.

Conclusion: Strategic Outlook for Intragastric Balloons

The intragastric balloon market is evolving within a broader shift toward multidisciplinary, outcomes-based obesity care. Strong public health need, minimally invasive delivery, and compatibility with structured lifestyle programs continue to support demand, particularly where endoscopy capacity and trained obesity teams are available.

Future performance will depend on clinical evidence, safety management, digital follow-up, and clear positioning alongside pharmacotherapy and bariatric surgery. Organizations that combine regulated devices with patient-centered support, responsible AI-enabled monitoring, and measurable outcomes are best placed to build durable competitive advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Intragastric Balloon Market, by Product Type

• 7.1. Single Balloon Systems
• 7.2. Multi-balloon Systems
• 7.3. Procedure-Free Balloons

8. Intragastric Balloon Market, by Filling Material

• 8.1. Saline-Filled Balloons
• 8.2. Gas-Filled Balloons

9. Intragastric Balloon Market, by Procedure Type

• 9.1. Endoscopic Placement
• 9.2. Non-Endoscopic Placement

10. Intragastric Balloon Market, by Duration of Implantation

• 10.1. Less Than 3 Months
• 10.2. 3-6 Months
• 10.3. More Than 6 Months

11. Intragastric Balloon Market, by Application

• 11.1. Weight Loss
• 11.2. Pre-Bariatric Surgery Weight Reduction
• 11.3. Post-Surgical Weight Maintenance
• 11.4. Metabolic Disorder Management

12. Intragastric Balloon Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Intragastric Balloon Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Intragastric Balloon Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Allurion Technologies, Inc.
• 16.2. Apollo Endosurgery, Inc.
• 16.3. Bariatric Solutions Ltd.
• 16.4. Baronova, Inc.
• 16.5. Boston Scientific Corporation
• 16.6. Cook Medical LLC
• 16.7. Endalis S.A.S.
• 16.8. EndoSphere S.r.l.
• 16.9. Helioscopie Medical Implants
• 16.10. Johnson & Johnson
• 16.11. Medicone GmbH
• 16.12. Medispar NV
• 16.13. Medsil
• 16.14. Medtronic plc
• 16.15. Obalon Therapeutics, Inc.
• 16.16. Silimed Industria de Implantes Ltda.
• 16.17. Spatz FGIA, Inc.
• 16.18. Suzhou Shenyun Medical Equipment Co., Ltd.